Statins reduce risk of Alzheimer's 67%
A new study has found that ongoing statin drug use was associated with a 67% reduction in the risk of Alzheimer's disease.
Published in a recent issue of Current Alzheimer Research, the 2,233-patient trial followed people aged 70 years and older for four years with annual assessments of cognitive changes and found a significant reduction in the risk of AD.
The USA's Nymox Pharmaceutical holds US and global patent rights for the use of statin drugs for the prevention and treatment of the common neurodegenerative disorder, including for patients at risk of AD because of vascular-related factors or disease.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze